|Awarded On||August 20, 2014|
|Title||Modulation of Autophagy: Phase II Study of Vorinostat Plus Hydroxychloroquine vs. Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC)|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Sukeshi Arora|
Colorectal cancer is a leading cause of cancer death in the United States and Texas. Patients with distant metastases have a 5-year survival rate of 13%, indicating the need for better treatments to improve survival in patients with advance colorectal cancer. For the past ten years, scientific evidence has shown treatments that inhibit factors that promote the blood supply (angiogenic inhibition) leads to improved survival in patients suffering with advance colorectal cancer. However, the benefit of angiogenic inhibition is modest once patients have failed initial angiogenic inhibition. Therefore, we need to discover other pathways in colorectal cancer proliferation that we can target so pat...